title: Hypertension, creatinine, and plasma renin activity in heart transplant recipients.
abstract: Development of de novo hypertension in a large proportion of orthotopic heart transplant recipients receiving cyclosporine has previously been reported. This hypertension is characterized by a persistence of increased peripheral resistance, sodium retention, and loss of nocturnal decline in BP. Vascular nephropathy with plasma renin activity (PRA) elevation from cyclosporine (CsA) may also be major factor in the progress of hypertension. To investigate this hypothesis, observations of BP, creatinine (Cr), and PRA were made in 144 heart transplant recipients followed for up to four and a half years. Median Cr was 133 mumol/l. Average diastolic BP and mean PRA values were significantly higher in patients with Cr greater than or equal to the median. Cr and PRA were significantly correlated (r = 0.4; P less than 0.001) in recipients with Cr greater than or equal to 133 mumols/l but not in those with Cr less than 133 mumols/l. In a selected subsample of heart transplant recipients with repeated Cr and PRA values, Cr and PRA appeared to increase longitudinally after transplant. These data are derived from a case series of patients managed on a variety of antihypertensive agents (excluding ACE inhibitors) needed to control the persistent hypertension.
authors.affiliation: Department of Medicine, School of Medicine, University of Pittsburgh, Pennsylvania 15261.
authors.forename: G H
authors.initials: GH
authors.lastname: Rutan
authors.forename: A P
authors.initials: AP
authors.lastname: Shapiro
authors.forename: M E
authors.initials: ME
authors.lastname: Thompson
authors.forename: R L
authors.initials: RL
authors.lastname: Nigalye
authors.forename: R H
authors.initials: RH
authors.lastname: McDonald
authors.forename: A M
authors.initials: AM
authors.lastname: Johnsen
authors.forename: A
authors.initials: A
authors.lastname: Trento
authors.forename: R L
authors.initials: RL
authors.lastname: Kormos
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003401:Creatine / Q000097:blood*; D003524:Cyclosporins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004039:Diet, Sodium-Restricted; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000009:adverse effects / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000453:epidemiology / Q000628:therapy; D012083:Renin / Q000097:blood*; D012189:Retrospective Studies; D012964:Sodium / Q000378:metabolism / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; D003524:Cyclosporins; D012964:Sodium; D012083:Renin; D003401:Creatine